Teachers Advisors LLC Increases Position in Rigel Pharmaceuticals, Inc. (RIGL)

Teachers Advisors LLC increased its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 6.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 297,167 shares of the biotechnology company’s stock after purchasing an additional 18,614 shares during the period. Teachers Advisors LLC owned 0.24% of Rigel Pharmaceuticals worth $811,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Parametric Portfolio Associates LLC boosted its position in Rigel Pharmaceuticals by 11.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 30,815 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 3,118 shares during the period. Rhumbline Advisers boosted its position in Rigel Pharmaceuticals by 6.0% during the 2nd quarter. Rhumbline Advisers now owns 139,814 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 7,910 shares during the period. Marshall Wace North America L.P. boosted its position in Rigel Pharmaceuticals by 0.5% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,988,193 shares of the biotechnology company’s stock worth $5,965,000 after purchasing an additional 9,867 shares during the period. JPMorgan Chase & Co. boosted its position in Rigel Pharmaceuticals by 0.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,461,550 shares of the biotechnology company’s stock worth $3,990,000 after purchasing an additional 11,836 shares during the period. Finally, American International Group Inc. lifted its holdings in Rigel Pharmaceuticals by 39.9% in the 1st quarter. American International Group Inc. now owns 74,900 shares of the biotechnology company’s stock worth $248,000 after buying an additional 21,345 shares in the last quarter. 76.29% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/11/06/teachers-advisors-llc-increases-position-in-rigel-pharmaceuticals-inc-rigl.html.

Rigel Pharmaceuticals, Inc. (RIGL) opened at $3.88 on Monday.

A number of equities analysts have commented on RIGL shares. BMO Capital Markets reiterated a “buy” rating and issued a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Monday, October 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. ValuEngine lowered shares of Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, BidaskClub lowered shares of Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Rigel Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $5.33.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

What are top analysts saying about Rigel Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rigel Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit